Patent 8685998
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Active provider: Google · gemini-2.5-flash
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Veloxis Pharmaceuticals AS
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Proceedings overview
There are no AIA trial proceedings (IPR, PGR, CBM) on file for U.S. Patent No. 8,685,998 according to the USPTO Open Data Portal API. A review of web search results also did not reveal any active or terminated PTAB proceedings for this patent. This indicates that the patent has not been challenged through the AIA trial process, and all claims (1-20) remain untested by the PTAB.
Strategic summary
As of today, May 31, 2026, U.S. Patent No. 8,685,998 has not been subjected to any AIA trial proceedings at the Patent Trial and Appeal Board. Consequently, all 20 claims of the patent, including the independent claims 1, 8, and 13, are currently valid and untested by the PTAB. There are no canceled, sustained, or modified claims resulting from IPR, PGR, or CBM actions.
Given the absence of PTAB proceedings, the estoppel landscape under 35 U.S.C. § 315(e)(2) is not applicable. A potential defendant facing assertion of this patent would not be barred from raising any prior art grounds in a future IPR. This means all prior art, whether raised in the original examination or newly discovered, remains available for challenging the patent's validity in an AIA trial. There are no apparent patterns of repeated challenges by the same petitioner or aggressive PTAB appeals by the patent owner, as no proceedings have occurred.
Recommended next steps
Since no PTAB activity exists for U.S. Patent No. 8,685,998, a defendant facing assertion of this patent may consider initiating an Inter Partes Review (IPR) to challenge its validity. The absence of prior PTAB challenges means there is no pre-existing record of validity determinations or claim cancellations to navigate. The patent has not been "hardened" by surviving IPRs, which suggests that an IPR could be a viable defense strategy.
Generated 5/31/2026, 12:46:31 AM